Figure 2.

(a-d): Preferred agent, dose, distance from limbus, follow-up schedule; among the respondents. (a): Anti-VEGF of choice for the treatment of ROP. (b): Preferred dose of anti-VEGF. (c): Distance from the limbus for injecting anti-VEGF. (d): Follow-up schedule post-injection